Remedy Product Studio — Research Document
Overview
Remedy Product Studio is a New York-based startup studio and strategic capital partner founded in 2012 by Oleg Krook and Igor Faybyshev, who met while working at Amplify (formerly Wireless Generation), an education-technology company. The firm blends equity investment with hands-on product and engineering services, partnering with early-stage startups to accelerate product velocity and increase fundraising success. Remedy is not a traditional venture capital firm; it operates as a Corporate Venture Capital (CVC) investor whose capital is paired with a product services relationship, and also deploys syndicate investments through SPVs that are not necessarily tied to services engagements.
The firm employs 51–200 people, with its North America office in New York City serving as the hub for Business Development, Investment, Consulting, and leadership, while its European office in Poland houses the majority of engineering and product development talent.
Investment Thesis
Remedy invests in technology businesses across five thematic pillars: (1) enhance personal wellbeing, (2) improve care delivery, (3) empower financial stability, (4) revolutionize how we engage in commerce, and (5) leverage data for global good. In practice, this translates to a primary focus on digital health, wellness, fintech, commerce, and data-driven vertical SaaS.
Remedy's differentiated model is the equity-for-service structure: rather than writing purely cash checks, Remedy exchanges a percentage of equity for product and engineering work, covering 20–33% of total project costs and distributed equally over 6–12 months to create predictable burn rates for founders. This aligns Remedy as both an investor and a hands-on operating partner, giving them meaningful skin in the game while delivering product velocity that a typical VC cannot offer.
When Remedy is highly conviction on a company, they invest off their balance sheet through the CVC model. They also co-invest alongside VCs through their Syndicate (SPV), targeting founders who want to bring Remedy in as a strategic partner but are not necessarily using their services.
Stage Focus
Remedy invests primarily at Pre-Seed through Series A. Their CVC model requires that an institutional lead investor is already in place and that the total round size is $1.5M or more before they write their equity-for-service check. They occasionally make exceptions for Pre-Seed founders with stellar track records. Partners are typically with Remedy for approximately three years, and the firm actively helps them through two fundraising cycles.
Check Size
Remedy's equity-for-service checks range from $50K to $200K, with the equity stake corresponding to the dollar investment amount at the lead investor's terms. The investment is designed to cover 20–33% of total project cost. Syndicate SPV investments may vary in size.
Team
- Oleg Krook, Founder & CEO: Co-founder with over 20 years of technical experience. Previously served as Director of Engineering at ClassPass, where he helped the company grow from Seed to Series B. Oleg and Igor Faybyshev met at Amplify (formerly Wireless Generation).
- Igor Faybyshev, Managing Partner, Head of Operations & Technology: Co-founder of Remedy. Built and leads the firm's engineering and operations infrastructure, including the Poland-based engineering team.
- Igor Moliver ("Iggy"), Managing Partner, Product & Investment Strategy: Joined Remedy in 2014 after the team helped build his startup OnePlayce. Previously worked at ESPN where he helped launch the WatchESPN app. Iggy introduced the formal investment component to Remedy's model.
- Jess Schram, Director of Investments & Incubations: Leads Remedy's investment decision-making and portfolio support. Author of Remedy's public investment announcements and key thought leadership pieces on the equity-for-service model.
- Cameron McCurdy, Director of Sales: Leads business development and new partner acquisition.
Recent Activity & Fund Status
Remedy executes 6–8 CVC investments per year plus 4–6 Syndicate investments per year, making them a prolific early-stage deployer relative to their check size. Recent portfolio additions include:
- Goose (pet care OS, $13.4M Seed round led with B Capital, First Round Capital, Imaginary Ventures, BoxGroup)
- Sol Health (Gen Z therapy platform, affordable mental health)
- Manatee (pediatric mental health, Seed extension, co-investors: GreyMatter, BCBS Kansas, Hopelab, Luminary Fund)
- She Matters (women's health)
Partner companies have collectively raised over $1 billion in total funding. Notable co-investors across the portfolio include Google Ventures, Greycroft, Serena Ventures, B Capital, First Round Capital, Imaginary Ventures, and BoxGroup.
Portfolio Highlights
Notable Exits:
- ClassPass (acquired by MindBody) — fitness and wellness marketplace; Oleg Krook served as Director of Engineering
- Block Six Analytics (acquired by Excel Sports Management) — sports data analytics
Growth-equity funded:
- H1 Insights — healthcare data platform
Active portfolio:
- Caraway Health — digital health with a category-defining early valuation
- Ash Wellness — at-home diagnostic health testing
- Wave Neuroscience — brain health and personalized Braincare platform
- Goose — operating system for pet care providers
- Manatee — pediatric mental health for families
- Sol Health — Gen Z therapy access
- She Matters — women's health
- Sommsation — wine discovery and commerce
- AssetDash — crypto portfolio tracking and fintech
- HealthReveal — preventive health analytics
- Zeamo — corporate fitness marketplace
- Every Mother — postpartum fitness
Geographic Focus
Primarily United States, with a strong concentration in New York City. The firm has meaningful reach across US markets through their syndicate network and co-investor relationships. Engineering talent is based in Poland (Europe).
Decision Process
Remedy's CVC investments are tied to a services engagement, so the decision involves both investment conviction and a product/services fit assessment. Decisions require partnership-level alignment (Oleg, Igor Faybyshev, Igor Moliver) and investment team sign-off (Jess Schram). They explicitly require an institutional lead already in place, meaning they follow rather than lead rounds. Syndicate investments are evaluated separately.
Founder Preferences
Remedy backs founders who:
- Plan to deploy fundraising capital into product development or technical team building
- Are working in health, wellness, finance, commerce, or data-driven sectors
- Have an institutional lead investor already committed to the round
- Are building digital products (mobile, web, platform businesses)
- Are open to a 2–3 year strategic partnership with active product and engineering involvement
They have a track record of backing repeat founders and teams with domain expertise. The Remedy team's background as both operators and former VCs gives them credibility with technical founding teams.